Franziska Blaeschke
University of California, San Francisco
H-index: 22
North America-United States
Top articles of Franziska Blaeschke
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies | Cell | Franziska Blaeschke Yan Yi Chen Ryan Apathy Bence Daniel Andy Y Chen | 2023/9/14 |
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails | Nature biotechnology | Brian R Shy Vivasvan S Vykunta Alvin Ha Alexis Talbot Theodore L Roth | 2023/4 |
Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections | Molecular Therapy | Tanja A Stief Theresa Kaeuferle Thomas R Müller Michaela Döring Lena M Jablonowski | 2022/1/5 |
RASA2 ablation in T cells boosts antigen sensitivity and long-term function | Nature | Julia Carnevale Eric Shifrut Nupura Kale William A Nyberg Franziska Blaeschke | 2022/9/1 |
Design and evaluation of TIM-3-CD28 checkpoint fusion proteins to improve anti-CD19 CAR T-cell function | Frontiers in Immunology | Franziska Blaeschke Eva Ortner Dana Stenger Jasmin Mahdawi Antonia Apfelbeck | 2022/4/6 |
CRISPR activation and interference screens decode stimulation responses in primary human T cells | Science | Ralf Schmidt Zachary Steinhart Madeline Layeghi Jacob W Freimer Raymund Bueno | 2022/2/4 |
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation | Elife | Dasmanthie De Silva Lucas Ferguson Grant H Chin Benjamin E Smith Ryan A Apathy | 2021/12/31 |
Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells | Molecular Therapy-Methods & Clinical Development | Nicole Cordes Carolin Kolbe Dominik Lock Tatjana Holzer Deborah Althoff | 2021/6/11 |
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins | Blood Cancer Journal | Franziska Blaeschke Dana Stenger Antonia Apfelbeck Bruno L Cadilha Mohamed-Reda Benmebarek | 2021/6/4 |
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering | Cell reports | Jennifer R Hamilton Connor A Tsuchida David N Nguyen Brian R Shy E Riley McGarrigle | 2021/6/1 |
TCF-1 regulates HIV-specific CD8+ T cell expansion capacity | JCI insight | Rachel L Rutishauser Christian Deo T Deguit Joseph Hiatt Franziska Blaeschke Theodore L Roth | 2021/2/2 |
CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy | Blood | Semjon Willier Paula Rothämel Maximilian Hastreiter Jonas Wilhelm Dana Stenger | 2020/10/22 |
Pooled knockin targeting for genome engineering of cellular immunotherapies | Cell | Theodore L Roth P Jonathan Li Franziska Blaeschke Jasper F Nies Ryan Apathy | 2020/4/30 |
Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients | Leukemia | Franziska Blaeschke Semjon Willier Dana Stenger Mareike Lepenies Martin A Horstmann | 2020/10 |
Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells | Journal for Immunotherapy of Cancer | Semjon Willier Johannes Raedler Franziska Blaeschke Dana Stenger Montserrat Pazos Escudero | 2020 |
CRISPR-Cas9-mediated glucocorticoid resistance in virus-specific T cells for adoptive T cell therapy posttransplantation | Molecular Therapy | Theresa Kaeuferle Larissa Deisenberger Lena Jablonowski Tanja A Stief Franziska Blaeschke | 2020/9/2 |
Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR) | The EMBO journal | Rui Dong Kendra A Libby Franziska Blaeschke Walker Fuchs Alexander Marson | 2020/8/17 |
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR | Blood, The Journal of the American Society of Hematology | Dana Stenger Tanja A Stief Theresa Kaeuferle Semjon Willier Felicitas Rataj | 2020/9/17 |
